ARIAD
Pharmaceuticals, Inc. ARIA today announced long-term
durability-of-response data from its Phase 1 trial of Iclusig®
(ponatinib) in heavily pretreated patients with resistant or intolerant
chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute
lymphoblastic leukemia (Ph+ ALL). The study shows that among
chronic-phase (CP) patients, the median durations of major and complete
cytogenetic responses, along with major molecular response, have yet to
be reached. The median follow-up for CP patients still on study is now
more than three years (36.5 months).
These data are being featured today at 8:00 a.m. CT in a poster
presentation at the Annual Meeting of the American Society of Clinical
Oncology
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in